NADH ENADA

The stabilized, orally absorbable form of NADH (ENADA) is a nutritional supplement available in the U.S. since 1995 and in the E.U. since 1997. Based on the patented formulation of this supplement, a number of clinical trials have been launched to prove scientifically that ENADA is effective. In order to get these studies started, an investigational new drag (IND) application was filed with the Food and Drag Administration (FDA). For FDA approval, it must be documented that ENADA (the stabilized oral form of NADH) is safe. For this reason, the maximum tolerated intravenous dose (MTD) of (3NADH (reduced form of beta-nicotinamide adenine... 

When taken orally, the stabilized form of NADH is absorbed in the small intestine. Stndies have shown that NADH passes the intestinal mncosa undegraded by passive diffusion. In a further study, it was demonstrated that ENADA-NADH passes the blood-brain barrier. When rats were fed with two tablets ENADA-NADH (5mg) an increase of the NADH level in the brain cortex was observed after 20min of intake as measured by laser-induced fluorescence. ... 

Following oral application of NADH (two tablets of ENADA [5mg NADH]=51mg/kg) the cortical fluorescence intensity was increased by about 20% compared with the control group. The results of this study provide convincing evidence... 

ENADA-NADH A PROTECTOR AGAINST CHEMOTOXICITY AND RADIATION... 

A number of cytostatic drags, including cisplatin, are carcinogenic. NADH is able to protect cells from the carcinogenic effects of these chemotherapeutic agents. Hence ENADA, the stabilized oral form of NADH, may present a safe, nontoxic, biological supplement for prevention of cancer. 

ENADA-NADH AS THERAPEUTIC CONCEPT FOR CERTAIN HUMAN CANCERS... 

NADH has been shown to inhibit the growth of murine fibrosarcoma and human laryngeal carcinoma cells in vitro.Based on these findings and the various biological functions, the stabilized oral form of ENADA has been used as treatment for certain... 

The following subsections describe a number of anecdotal cases in which ENADA-NADH was used as an anticancer therapy. 

G.B.). The patient was recommended to take four 5-mg tablets of ENADA per day. He was already taking selenium, vitamin C, and vitamin E. In January 2002, the size of the tumor was, as verified by MRT, to be the size of a cherry. The therapy with NADH was continued. In July 2002, an MRT report from the University of Amsterdam stated that no tumor was detectable. 

Reibnegger, G., Greilberger, J., Juergens, G., and Oettl, K., The antioxidative capacity of ENADA-NADH in humans, ICMAN Proceedings (2nd Int. Conf. on Mechanisms and Actions of Nutraceuticals), 37,2002. 

Birkmayer, J.G.D. and Nadlinger, K., Safety of stabilized, orally absorbable, reduced nicotinamide adenine dinucleotide (NADH) a 26-week oral tablet administration of ENADA /NADH for chronic toxicity study in rats. Drugs Exptl. Clin. Res., 28 (5), 185,2002. 

---